Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New electric zapper targets heart flutter during surgery

NCT ID NCT06355063

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device that uses short electrical pulses to treat atrial fibrillation (an irregular heartbeat) during heart surgery. About 30 adults aged 18 to 85 who need heart surgery and have a history of atrial fibrillation will take part. The device aims to create scar tissue around the heart's veins to block faulty signals and restore a normal rhythm. Researchers will check if the procedure is safe and works well in the short and long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject must be between 18 and 85 years of age * Subject is willing and capable of providing Informed Consent to undergo study procedures which includes surgical AF ablation and completing follow-up visits as specified in the clinical study protocol * Subject has history of documented atrial fibrillation within one year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), holter monitor or telemetry strip * Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, or Coronary artery bypass procedures * Left ventricular ejection fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history) * Subject has a life expectancy of at least 5 years Exclusion Criteria: * Subject has an implantable electronic medical device. (i.e., pacemaker, ICD or CRT) or left atrial appendage device * Subject has a prosthetic heart valve * Stand-alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery * Previous surgical Maze procedure * Prior cardiac surgery (Redo) * Wolff-Parkinson-White syndrome or other Supra-Ventricular arrhythmia, Atrioventricular (AV) nodal reentry * Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair. * Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation) * Class IV New York Heart Association (NYHA) heart failure symptoms * Prior history of cerebrovascular accident or TIA within 6 months or at any time if there is residual neurological deficit * Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment * Need for emergent cardiac surgery (i.e., cardiogenic shock) * Known carotid artery stenosis greater than 80% * Current diagnosis of active systemic infection * Severe peripheral arterial occlusive disease defined as claudication with minimal exertion * Renal failure requiring dialysis or hepatic failure * A known drug and/or alcohol addiction * Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study * Pregnancy or desire to get pregnant within 12-months of the study treatment * Preoperative need for an intra-aortic balloon pump or intravenous inotropes * Subjects who have been treated with thoracic radiation * Subjects in current chemotherapy * Subjects on long term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases) * Subjects with known hypertrophic obstructive cardiomyopathy * Subjects with known cold agglutinin * History of abnormal bleeding and/or clotting disorder * Contraindication to anticoagulation (i.e., Heparin, Dabigatran, Apixaban, Vitamin K Antagonists such as warfarin) * Solid organ or hematologic transplant, or currently being evaluated for an organ transplant * Body mass index \> 40 kg/m2 * Use of any other investigational drug, therapy, or device within 30 days prior to enrollment or concurrent participation in another research study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ablation of atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Academic Medical Center

    ACTIVE_NOT_RECRUITING

    Amsterdam, Netherlands

  • Catharina Hospital

    RECRUITING

    Eindhoven, Netherlands

  • Maastricht University Medical Center+ (MUMC+)

    ACTIVE_NOT_RECRUITING

    Maastricht, Netherlands

  • Medical University of Vienna

    RECRUITING

    Vienna, Austria

  • St. Antonius Hospital

    RECRUITING

    Nieuwegein, Netherlands

  • State Medical Institute of the Ministry of Interior Affairs and Administration

    RECRUITING

    Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.